{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:15:47Z","timestamp":1790234147049,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1016\/j.clinthera.2004.11.009","type":"journal-article","created":{"date-parts":[[2005,1,6]],"date-time":"2005-01-06T07:15:12Z","timestamp":1104995712000},"page":"1800-1807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Pharmacodynamic modeling of carbapenems andfluoroquinolones against bacteria that produce extended-spectrum beta-lactamases"],"prefix":"10.1016","volume":"26","author":[{"given":"Leticia R","family":"Moczygemba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Frei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2004.11.009_bib1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1086\/324742","article-title":"Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime","volume":"34","author":"Wong-Beringer","year":"2002","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.clinthera.2004.11.009_bib2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1592\/phco.21.11.920.34529","article-title":"Extended-spectrum beta-lactamases: Epidemiology, detection, and treatment","volume":"21","author":"Nathisuwan","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2004.11.009_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-8579(02)00249-2","article-title":"Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. andESBL-producing Klebsiella spp.: Report from the SENTRY Antimicrobial Surveillance Program (USA, 1997\u20132000)","volume":"21","author":"Jones","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2004.11.009_bib4","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically","author":"National Committee for Clinical Laboratory Standards","year":"2003"},{"key":"10.1016\/j.clinthera.2004.11.009_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0732-8893(01)00353-4","article-title":"Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: Regional resultsfrom SENTRY Antimicrobial Surveillance Program (1998\u20131999)","volume":"42","author":"Bell","year":"2002","journal-title":"Diagn Microbial Infect Dis."},{"key":"10.1016\/j.clinthera.2004.11.009_bib6","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/CMR.14.4.933-951.2001","article-title":"Extended-spectrum beta-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat","volume":"14","author":"Bradford","year":"2001","journal-title":"Clin Microbial Rev."},{"key":"10.1016\/j.clinthera.2004.11.009_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1128\/AAC.35.1.164","article-title":"Properties of plasmids responsible for production of extended-spectrum beta-lactamases","volume":"35","author":"Jacoby","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.009_bib8","first-page":"413","article-title":"Antimicrobial resistance among gram-negative organisms in the intensive care unit","volume":"9","author":"Clark","year":"2003","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.clinthera.2004.11.009_bib9","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.45.10.2831-2837.2001","article-title":"Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases","volume":"45","author":"Livermore","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.009_bib10","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1128\/AAC.45.6.1860-1867.2001","article-title":"In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia","volume":"45","author":"Livermore","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.009_bib11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.46.1.220-224.2002","article-title":"In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds","volume":"46","author":"Hoellman","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.009_bib12","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/jac\/dkg237","article-title":"Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: Analysis of pooled clinical trial data","volume":"51","author":"Gesser","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.009_bib13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1086\/313719","article-title":"Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase produc tion in Klebsiella pneumoniae isolatescausing bacteremia","volume":"30","author":"Paterson","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.009_bib14","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1086\/322667","article-title":"Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"33","author":"Lautenbach","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2004.11.009_bib15","first-page":"542","article-title":"Prevention of resistance: A goal for dose selection for antimicrobial agents","volume":"36","author":"Drusano","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.009_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0924-8579(02)00022-5","article-title":"Animal model pharmacokinetics and pharmacodynamics: A critical review","volume":"19","author":"Andes","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2004.11.009_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.009_bib18","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1128\/AAC.36.7.1400","article-title":"Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration","volume":"36","author":"Signs","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.009_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1128\/AAC.40.1.105","article-title":"Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin","volume":"40","author":"Dreetz","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.009_bib20","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1128\/AAC.46.11.3506-3511.2002","article-title":"Pharmacokinetics of ertapenem in healthy young volunteers","volume":"46","author":"Majumdar","year":"2002","journal-title":"Antmicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.009_bib21","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1128\/AAC.41.10.2256","article-title":"Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses","volume":"41","author":"Chien","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.009_bib22","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1128\/AAC.45.7.2122-2125.2001","article-title":"Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers","volume":"45","author":"Chow","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.009_bib23","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1128\/AAC.39.12.2635","article-title":"Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans","volume":"39","author":"Nakashima","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.009_bib24","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1128\/AAC.36.5.993","article-title":"Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses","volume":"36","author":"Lettieri","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2004.11.009_bib25","series-title":"Levaquin","year":"2004"},{"key":"10.1016\/j.clinthera.2004.11.009_bib26","series-title":"Tequin","year":"2004"},{"key":"10.1016\/j.clinthera.2004.11.009_bib27","series-title":"Cipro","year":"2004"},{"key":"10.1016\/j.clinthera.2004.11.009_bib28","series-title":"Merrem","year":"2004"},{"key":"10.1016\/j.clinthera.2004.11.009_bib29","series-title":"Primaxin","year":"2004"},{"key":"10.1016\/j.clinthera.2004.11.009_bib30","series-title":"Invanz","year":"2004"},{"key":"10.1016\/j.clinthera.2004.11.009_bib31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0732-8893(00)00185-1","article-title":"The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: Fluoroquinolone pharmacodynamics against Streptococcuspneumoniae","volume":"38","author":"Ambrose","year":"2000","journal-title":"Diagn Microbial Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.009_bib32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0732-8893(03)00112-3","article-title":"Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: Report from the MYSTIC Program (2002) in North America","volume":"47","author":"Rhomberg","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2004.11.009_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0924-8579(99)00091-6","article-title":"Comparative activities of six different fluoroquinolones against 9,682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY Surveillance Programme","volume":"12","author":"Schmitz","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2004.11.009_bib34","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1046\/j.1469-0691.2003.00555.x","article-title":"Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe","volume":"9","author":"Jones","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2004.11.009_bib35","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1128\/AAC.43.5.1170","article-title":"In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates","volume":"43","author":"Kohler","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2004.11.009_bib36","first-page":"ii11","article-title":"In vitro activity of ertapenem: Review of recent studies","volume":"53","author":"Wexler","year":"2004","journal-title":"Antimicrob Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2004.11.009_bib37","first-page":"ii23","article-title":"Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians","volume":"53","author":"Nix","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2004.11.009_bib38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1067\/mcp.2002.122526","article-title":"Tissue distribution of imipenem in critically ill patients","volume":"71","author":"Tegeder","year":"2002","journal-title":"Clin Pharmacol Ther."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0149291804803448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0149291804803448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T07:07:46Z","timestamp":1762153666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/0149291804803448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["0149291804803448"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2004.11.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic modeling of carbapenems andfluoroquinolones against bacteria that produce extended-spectrum beta-lactamases","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2004.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Excerpta Medica, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}